Pharma Access

Our Approach

Senior expertise without the layers.

Market access decisions are often complex, but the advice clients receive should not be. We work directly with senior market access and payer experts rather than relying on large teams of junior consultants.

How we work

Strategic

We focus on the decisions that will affect access, not simply on producing deliverables.

Payer-informed

We bring practical understanding of how Canadian public and private payers and HTA bodies assess value.

Evidence-driven

We connect clinical, economic and real-world evidence to the questions that matter for reimbursement.

Pragmatic

We recognize that market access strategies need to work within real-world evidence, timing, resource and commercial constraints.

Collaborative

We work as an extension of your team and can complement internal capabilities or larger consulting partners.

Direct

Every engagement is delivered by the senior advisors you meet at the outset. No handover, no layers.

Working Together

Two perspectives. One integrated view of access.

Shannon and Marc bring complementary expertise across strategy, payer insight and technology. Together we can support clients across the interconnected questions that shape successful access.

This integrated perspective allows us to connect strategy, evidence, payer insight, pricing and reimbursement rather than considering each in isolation, and to build the tools that put the answer into practice.

Meet the advisors
1

What will payers value?

2

What evidence will they expect?

3

How should the clinical and economic value proposition be positioned?

4

What pricing and reimbursement strategy is realistic?

5

What are the key risks, and how can they be addressed?

6

Where could technology or AI make this faster and more repeatable?

Who We Work With

We support

  • Pharmaceutical companies
  • Biotechnology companies
  • Emerging and specialty pharma
  • Market access and HEOR teams
  • Medical affairs teams
  • Commercial and launch teams
  • Investors and organizations assessing market opportunities
  • Larger consulting firms seeking senior Canadian market access expertise

Our model is flexible. We can lead a focused strategic project, provide an independent expert perspective, or complement an existing internal or consulting team.

Selected Engagements

Across the product lifecycle

Stage 01

Early Development

Assessing payer expectations and evidence requirements before key development decisions are made.

Stage 02

Pre-Launch

Building Canadian access strategy, identifying risks and strengthening the value proposition ahead of launch.

Stage 03

HTA Submission

Providing strategic direction for CADTH, INESSS and provincial reimbursement submissions.

Stage 04

Pricing & Reimbursement

Assessing pricing considerations and their implications for access.

Stage 05

Payer Engagement

Preparing for payer discussions and translating stakeholder feedback into strategic action.

Stage 06

Post-Launch

Using emerging evidence, payer feedback and real-world experience to refine access strategy.

Where would senior input make the most difference?

We can lead a focused strategic project, provide an independent expert perspective, or work alongside your existing team.

Let's talk
Pharma Access

Canadian Market Access Advisory

Senior market access, payer and pricing advisory for pharmaceutical and biotech companies navigating the Canadian healthcare system.